EUCTR2014-004380-20-Outside-EU/EEA进行中（未招募）不适用
A Double-blind, Double-dummy, Parallel, Active-controlled, Randomized and Multi-center Trial to Investigate Efficacy and Safety in Subjects With Iron Deficiency Anemia for Ferrous (II) Glycine Sulphate Complex Versus Polyferose Capsules Therapy
Sanol GmbH0 个研究点目标入组 240 人开始时间: 2015年2月10日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •An iron deficiency anemia patient with Serum Ferritin < 12 ng/mL, serum Hb-values >60 and < 120 g/L in males, < 110 g/L in females
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 190
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •- With any Mal-absorption Syndrome
- •- With a history of Thalassemia or Sickle Cell Anemia
- •- With untreated concurrent Vitamin B12 or Folate deficiency at Baseline
研究者
相似试验
未知
3 期
A Randomised, Double-blind, Double-dummy, Parallel Group, International (Asian), Multicenter, Phase 3 Study to Assess Safety and Efficacy of AZD6140 on Top of Low Dose Acetyl Salicylic Acid (ASA) Versus Clopidogrel on Top of Low Dose ASA in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes(ACS) for Whom PCI is PlannedAcute Coronary Syndrome (Percutaneous Coronary Intervention)JPRN-jRCT2080221435AstraZeneca
尚未招募
3 期
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple SclerosisRelapsing Multiple SclerosisLBCTR2023015151ovartis Pharma AG16
进行中（未招募）
不适用
A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3.MedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2007-003353-90-DEBoehringer Ingelheim Pharma GmbH & Co. KG132
进行中（未招募）
1 期
A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.EUCTR2007-003353-90-FRBOEHRINGER INGELHEIM145
进行中（未招募）
1 期
A double-blind, double-dummy, randomized, parallel groups study toassess the Efficacy, Safety and Tolerability of switching patients withearly Parkinson’s disease (PD) from Pramipexole IR to Pramipexole ERor Pramipexole IR.Male or female patients with idiopathic Parkinson's disease diagnosed within 5 years, with a modified Hoehn and Yahr scale of 1 to 3.MedDRA version: 9.1Level: LLTClassification code 10061536Term: Parkinson's diseaseEUCTR2007-003353-90-NLBoehringer Ingelheim145